Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RG1209 | Human P2RY2 Stable Cell Line-1321N1 | Inquiry |
| CSC-RG1746 | Rat P2ry2 Stable Cell Line-1321N1 | Inquiry |
| CSC-DC011210 | Panoply™ Human P2RY2 Knockdown Stable Cell Line | Inquiry |
| CSC-SC011210 | Panoply™ Human P2RY2 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT2598 | Mouse P2ry2 Knockout Cell Line-ATDC5 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD11717Z | Human P2RY2 adenoviral particles | Inquiry |
| LV20834L | human P2RY2 (NM_176072) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH369588 | shRNA set against Human P2RY2 (NM_002564.2) | Inquiry |
| SHH369592 | shRNA set against Mouse P2RY2 (NM_008773.3) | Inquiry |
| SHR085304 | shRNA set against Mouse P2ry2(NM_008773.3) | Inquiry |
| SHH369596 | shRNA set against Rat P2RY2 (NM_017255.1) | Inquiry |
| SHR085296 | shRNA set against Human P2RY2(NM_002564.2) | Inquiry |
| SHR085488 | shRNA set against Rat P2ry2(NM_017255.1) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| OE-PNDC000541 | Human P2RY2 Nanodisc | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFG010813 | Human P2RY2 cDNA Clone(NM_176071.1) | Inquiry |
| MiUTR1R-05582 | P2RY2 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-08845 | P2RY2 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-07446 | P2RY2 miRNA 3'UTR clone | Inquiry |
| CDFR011305 | Rat P2ry2 cDNA Clone(NM_017255.1) | Inquiry |
| CDFH013562 | Human P2RY2 cDNA Clone(NM_002564.2) | Inquiry |
| CDFG011238 | Human P2RY2 cDNA Clone(NM_176072.1) | Inquiry |
| MiUTR3H-03102 | P2RY2 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-03103 | P2RY2 miRNA 3'UTR clone | Inquiry |
| CDCS417531 | Human P2RY2 ORF Clone (BC012104) | Inquiry |
| CDCR382617 | Human P2RY2 ORF Clone(NM_176072.1) | Inquiry |
| CDCR382615 | Human P2RY2 ORF Clone(NM_176071.1) | Inquiry |
| CDCR378319 | Rat P2ry2 ORF Clone(NM_017255.1) | Inquiry |
| CDCR283518 | Human P2RY2 ORF Clone(NM_002564.2) | Inquiry |
| CDCH016243 | Mouse P2RY2 ORF clone(NM_008773.3) | Inquiry |
| CDCS417532 | Human P2RY2 ORF Clone (BC028135) | Inquiry |
| CDCB182278 | Rabbit P2RY2 ORF clone (XM_008264329.1) | Inquiry |
In developed countries, among the gynecological diseases, epithelial ovarian cancer patients have the highest mortality rate. Elevation of their mortality is accompanied with dissemination of tumor cells throughout the peritoneal cavity and occurrence of the secondary tumors in various organs. Thus, the identification of pathways regulating the cell invasiveness is critical of understanding the lethality implicated mechanisms of this disease. In response to various stimuli, ATP is released from Cells, and this behavior plays a pivotal role in mediating autocrine and paracrine signaling events. There is mounting evidence showing that metabolic deregulation induced by cancer cells leads to an increase in ATP production. The fluctuation of the ATP level is enough to activate P2 receptors, more than this, other nucleotides can activate two families of purinergic receptors, named as P2RX and P2RY receptors. P2RY, a G protein-coupled receptor (GPCR), can be activated by purines and pyrimidines for signaling cascade through different second messengers depending on the heterotrimeric G protein associated with them. Human P2RY2 receptor can be activated ATP and UTP at the similar potency with purines or pyrimidines.
In physiological and pathophysiological processes, many studies have demonstrated the participation of the P2RY2 receptor in inducing migration or EMT process and transactivation of the epidermal growth factor receptor (EGFR) is important for this migration. The activator of the EGFR (a family of membrane receptors with intrinsic tyrosine kinase activity), epidermal growth factor (EGF) has been proven to be a participant in the EGF-EGFR-mediated signaling in the progression and invasiveness of different types of carcinomas. Involvement of EGFR activation induced migratory phenotype in the EMT process was observed in ovarian carcinoma cells. And EGFR activity in ovarian carcinoma-derived cells has also been found to be related with proliferation regulation. Trans-activation of EGFR by other receptors is a well-established phenomenon in cancer models. With specialty in ovarian carcinoma, EGFR has been demonstrated to be transactivated by the chemokine CXCL1 and the membrane estrogen receptor GPER1.
It has been well known that P2RY2 has involvement in the regulation of cell proliferation and apoptosis. In the established models, included middle cerebral artery occlusion (MCAO) model in rats and oxygen-glucose deprivation (OGD) model in PC12 cells, expressions level of the P2RY2 was up-regulated, while SOD activity and myocytic and mitochondrial fusion factors were down-regulated, and overexpression of P2RY2 could reverse this phenomenon. P2RY2 expression up-regulation induced Yes-associated protein (YAP) phosphorylation or some other promotions of the nuclear translocation of YAP can inhibit cell apoptosis, and it can be reversed by YAP inhibitor verteporfin.
Figure 1. Involvement of P2RY2 in the regulation of cell proliferation and apoptosis. (Long-xing xue, et al. 2021)
References: